Medco Research's Adenoscan approved May 18; Fujisawa will market product.
This article was originally published in The Gray Sheet
Executive Summary
MEDCO RESEARCH ADENOSCAN APPROVED MAY 18 by FDA as an injectable coronary vasodilator to be used as "an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately" to undergo stress testing for diagnosis of coronary artery disease. The adenosine product is composed of the endogenous naturally occurring nucleoside 6-amino-9-beta-D-ribofuranosyl-9-H-purine. FDA deemed the product "approvable" April 18.